Recombinant Coagulation Factor IX Albumin Fusion Protein

BIOLOGICAL2 trials

Sponsors

CSL Behring

Conditions

Hemophilia B

Phase 1

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

CompletedNCT01233440

CSL BehringHemophilia B

Start: 2010-10-31End: 2011-07-31Updated: 2012-01-31

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

CompletedNCT01361126

CSL BehringHemophilia B

Start: 2011-07-31End: 2012-07-31Updated: 2016-05-09